Immunotherapy of distant metastatic disease
Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon alpha, and/or with various chemotherapeutic agents (biochemotherapy) is associated with significa...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2009 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/36407 |
| Acceso en línea: | https://hdl.handle.net/10171/36407 |
| Access Level: | acceso abierto |
| Palabra clave: | Anti-CTLA-4 Humans Adoptive immunotherapy Interferon Interleukin Melanoma Cancer vaccines |
| id |
ES_45b4a682d2432c63c1cfeb6610aaaabb |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/36407 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Immunotherapy of distant metastatic diseaseSchadendorf, D. (D.)|||/items/4104fc1f-acf3-4090-92b7-eff336d98ff5Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0ccBastholt, L. (L.)|||/items/60d5fbad-4439-4040-83f4-10e4e40fd57eCinat, G. (G.)|||/items/8abd5400-aea5-47bb-99b6-4ccde3045ff7Dreno, B. (B.)|||/items/71c0e54c-d3c3-4641-a34e-309a4ae774e2Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37Espinosa, E. (E.)|||/items/9f1b179c-44ba-4f52-8372-1355ece34eb9Guo, J. (J.)|||/items/5b271bf4-f87b-4b88-a7d5-b261b5ecaf24Hauschild, A. (A.)|||/items/1dc435a8-48e6-4659-a79a-99f0aad8901bPetrella, T. (T.)|||/items/4bc89049-d2c8-4a43-9213-a6cae0311215Schachter, J. (J.)|||/items/f741706c-fd89-41e1-b022-ecbbba045177Hersey, P. (P.)|||/items/38c6e9d0-7d74-4127-92e0-fb0d43952cc6Anti-CTLA-4HumansAdoptive immunotherapyInterferonInterleukinMelanomaCancer vaccinesImmunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon alpha, and/or with various chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed.Oxford University Press (OUP)Dadun. Depósito Académico Digital Universidad de Navarra20142014-08-2820092009-08-0120092009-08-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/36407reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/364072026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Immunotherapy of distant metastatic disease |
| title |
Immunotherapy of distant metastatic disease |
| spellingShingle |
Immunotherapy of distant metastatic disease Schadendorf, D. (D.)|||/items/4104fc1f-acf3-4090-92b7-eff336d98ff5 Anti-CTLA-4 Humans Adoptive immunotherapy Interferon Interleukin Melanoma Cancer vaccines |
| title_short |
Immunotherapy of distant metastatic disease |
| title_full |
Immunotherapy of distant metastatic disease |
| title_fullStr |
Immunotherapy of distant metastatic disease |
| title_full_unstemmed |
Immunotherapy of distant metastatic disease |
| title_sort |
Immunotherapy of distant metastatic disease |
| dc.creator.none.fl_str_mv |
Schadendorf, D. (D.)|||/items/4104fc1f-acf3-4090-92b7-eff336d98ff5 Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc Bastholt, L. (L.)|||/items/60d5fbad-4439-4040-83f4-10e4e40fd57e Cinat, G. (G.)|||/items/8abd5400-aea5-47bb-99b6-4ccde3045ff7 Dreno, B. (B.)|||/items/71c0e54c-d3c3-4641-a34e-309a4ae774e2 Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37 Espinosa, E. (E.)|||/items/9f1b179c-44ba-4f52-8372-1355ece34eb9 Guo, J. (J.)|||/items/5b271bf4-f87b-4b88-a7d5-b261b5ecaf24 Hauschild, A. (A.)|||/items/1dc435a8-48e6-4659-a79a-99f0aad8901b Petrella, T. (T.)|||/items/4bc89049-d2c8-4a43-9213-a6cae0311215 Schachter, J. (J.)|||/items/f741706c-fd89-41e1-b022-ecbbba045177 Hersey, P. (P.)|||/items/38c6e9d0-7d74-4127-92e0-fb0d43952cc6 |
| author |
Schadendorf, D. (D.)|||/items/4104fc1f-acf3-4090-92b7-eff336d98ff5 |
| author_facet |
Schadendorf, D. (D.)|||/items/4104fc1f-acf3-4090-92b7-eff336d98ff5 Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc Bastholt, L. (L.)|||/items/60d5fbad-4439-4040-83f4-10e4e40fd57e Cinat, G. (G.)|||/items/8abd5400-aea5-47bb-99b6-4ccde3045ff7 Dreno, B. (B.)|||/items/71c0e54c-d3c3-4641-a34e-309a4ae774e2 Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37 Espinosa, E. (E.)|||/items/9f1b179c-44ba-4f52-8372-1355ece34eb9 Guo, J. (J.)|||/items/5b271bf4-f87b-4b88-a7d5-b261b5ecaf24 Hauschild, A. (A.)|||/items/1dc435a8-48e6-4659-a79a-99f0aad8901b Petrella, T. (T.)|||/items/4bc89049-d2c8-4a43-9213-a6cae0311215 Schachter, J. (J.)|||/items/f741706c-fd89-41e1-b022-ecbbba045177 Hersey, P. (P.)|||/items/38c6e9d0-7d74-4127-92e0-fb0d43952cc6 |
| author_role |
author |
| author2 |
Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc Bastholt, L. (L.)|||/items/60d5fbad-4439-4040-83f4-10e4e40fd57e Cinat, G. (G.)|||/items/8abd5400-aea5-47bb-99b6-4ccde3045ff7 Dreno, B. (B.)|||/items/71c0e54c-d3c3-4641-a34e-309a4ae774e2 Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37 Espinosa, E. (E.)|||/items/9f1b179c-44ba-4f52-8372-1355ece34eb9 Guo, J. (J.)|||/items/5b271bf4-f87b-4b88-a7d5-b261b5ecaf24 Hauschild, A. (A.)|||/items/1dc435a8-48e6-4659-a79a-99f0aad8901b Petrella, T. (T.)|||/items/4bc89049-d2c8-4a43-9213-a6cae0311215 Schachter, J. (J.)|||/items/f741706c-fd89-41e1-b022-ecbbba045177 Hersey, P. (P.)|||/items/38c6e9d0-7d74-4127-92e0-fb0d43952cc6 |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
Anti-CTLA-4 Humans Adoptive immunotherapy Interferon Interleukin Melanoma Cancer vaccines |
| topic |
Anti-CTLA-4 Humans Adoptive immunotherapy Interferon Interleukin Melanoma Cancer vaccines |
| description |
Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon alpha, and/or with various chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed. |
| publishDate |
2009 |
| dc.date.none.fl_str_mv |
2009 2009-08-01 2009 2009-08-01 2014 2014-08-28 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/36407 |
| url |
https://hdl.handle.net/10171/36407 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Oxford University Press (OUP) |
| publisher.none.fl_str_mv |
Oxford University Press (OUP) |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra |
| instname_str |
Universidad de Navarra |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869407179334746112 |
| score |
15,301603 |